Surgical Innovation to End Nerve Pain

Neuroma and neuropathic pain are common, expensive, and debilitating complications of nerve injuries and amputations and occur in up to 48% of amputees. This limits mobility and can lead to severe psychosocial consequences and opioid addiction in patients already affected by debilitating conditions. Surgical approaches to prevent and/or treat neuroma and neuropathic pain are either ineffective or effective, but too complex to reach a significant portion of those affected (<3.5% nationally).

 

Renerva® PNM-CAP is a fully developed, packaged, and terminally sterilized bioabsorbable nerve capping device made of porcine nerve extracellular matrix. PNM-CAP can be easily secured to one or more amputated nerve stumps during the amputation procedure. The proprietary internal neuroinhibitory 3D matrix of PNM-CAP prevents nerve growth and entanglement, leading to effective and long-term inhibition of neuroma and neuropathic pain.

 

Unlike existing solutions to prevent and treat neuroma, which are associated with either shortcomings, negligible adoption, limited patient access, and/or significant trade-offs, Renerva® PNM-CAP offers the opportunity to achieve meaningful and permanent prevention of neuroma and pain with a simple-to-use and affordable solution that can achieve broad utilization.

​

We are seeking partners aligned with our vision of improving patient outcomes while capturing a sizable and underserved market. Please use the link below to obtain more information regarding our investment opportunities.